

**Request:** Industry

**Date:** January 2011

**Purpose:** The data will be used internally only to populate patient forecasting models which are used for business planning. Business planning includes stock requirements forecasts, revenues forecasts and developing a general understanding of the market.

Table 1: CD4 category by treatment regimens (reproduction of ASR report table 7.1.1 – specifically CD4 re-categorisation of CD4) (a) 2008. (b) 2009.

(a) 2008

	Regimen										Total <sup>1</sup>
	Rx NAIVE		MONO/DUAL		3+ NNRTI+PI,+/- NRTI		3+ NRTI+/- PI,NO NNRTI		3+ NRTI+NNRTI, NO PI		
	N	%	N	%	N	%	N	%	N	%	
<200	8	4	22	10	21	10	89	41	76	35	216
200-349	19	5	36	10	34	9	142	39	130	36	361
350-499	45	9	41	8	37	7	184	37	190	38	497
>500	171	17	70	7	67	7	288	29	401	40	997
<b>Total</b>	<b>243</b>	<b>12</b>	<b>169</b>	<b>8</b>	<b>159</b>	<b>8</b>	<b>703</b>	<b>34</b>	<b>797</b>	<b>38</b>	<b>2071</b>

1. Patients enrolled in AHOD and who had a visit follow-up during 2008

(b) 2009

	Regimen										Total <sup>2</sup>
	Rx NAIVE		MONO/DUAL		3+ NNRTI+PI,+/- NRTI		3+ NRTI+/- PI,NO NNRTI		3+ NRTI+NNRTI, NO PI		
	N	%	N	%	N	%	N	%	N	%	
<200	5	2	17	8	21	10	84	42	75	37	202
200-349	19	6	28	8	34	10	131	39	124	37	336
350-499	38	8	36	8	40	8	184	39	179	38	477
>500	133	14	54	6	70	7	290	31	392	42	939
<b>Total</b>	<b>195</b>	<b>10</b>	<b>135</b>	<b>7</b>	<b>165</b>	<b>8</b>	<b>689</b>	<b>35</b>	<b>770</b>	<b>39</b>	<b>1954</b>

2. Patients enrolled in AHOD and who had a follow-up visit during 2009. Patient totals for 2009 are less than 2008 totals due to a cohort site unable to provide follow-up data in 2009 for a large proportion of its cohort.

Table 2: CD4 at the time of commencing antiretroviral treatment.

Year	CD4+ (cells/ $\mu$ L)								Total <sup>1</sup>
	<200		200-349		350-499		>500		
	N	%	N	%	N	%	N	%	
<=2000	5	21	7	29	6	25	6	25	24
2001	4	20	11	55	3	15	2	10	20
2002	9	45	7	35	2	10	2	10	20
2003	3	18	7	41	4	24	3	18	17
2004	8	30	12	44	4	15	3	11	27
2005	4	19	8	38	6	29	3	14	21
2006	7	18	19	50	9	24	3	8	38
2007	9	35	12	46	3	12	2	8	26
2008	4	14	15	52	7	24	3	10	29
2009	6	16	17	46	6	16	8	22	37
<b>Total</b>	59	23	115	44	50	19	35	14	259

1. Patients need to have commenced their first antiretroviral treatment (ART) *AFTER* having enrolled in AHOD; and have a CD4 measure available 1 year prior to commencing ART.

Table 3: Top ART combinations (3+ ARVs), reproduction of Table 7 in AHOD Annual report for years (a) 2007, (b) 2008, (c) 2009.

(a) 2007 <sup>1</sup>				(b) 2008 <sup>2</sup>				(c) 2009 <sup>3</sup>				
	Combination	N	%	Cum %	Combination	N	%	Cum %	Combination	N	%	Cum %
1	TRUVADA-EFAV	123	6.2	6.2	TRUVADA-NEV	147	7.2	7.2	TRUVADA-EFAV	170	8.9	8.9
2	KIVEXA-NEV	108	5.4	11.6	TRUVADA-EFAV	141	6.9	14.2	TRUVADA-NEV	160	8.4	17.3
3	TRUVADA-NEV	99	5.0	16.6	KIVEXA-NEV	121	5.9	20.1	KIVEXA-NEV	118	6.2	23.4
4	ABC-LAM-NEV	79	4.0	20.6	TRUVADA-ATAZ-RITON	91	4.5	24.6	TRUVADA-ATAZ-RITON	88	4.6	28.0
5	KIVEXA-EFAV	78	3.9	24.5	ABC-LAM-NEV	80	3.9	28.5	KIVEXA-EFAV	71	3.7	31.7
6	CBV-NEV	67	3.4	27.8	KIVEXA-EFAV	80	3.9	32.4	ABC-LAM-NEV	56	2.9	34.7
7	TRUVADA-ATAZ-RITON	67	3.4	31.2	CBV-NEV	47	2.3	34.7	TRUVADA-KALETRA	54	2.8	37.5
8	CBV-EFAV	45	2.3	33.5	KIVEXA-ATAZ-RITON	45	2.2	37.0	EMTRIC-EFAV-TENOF	49	2.6	40.0
9	KIVEXA-ATAZ-RITON	44	2.2	35.7	TRUVADA-KALETRA	44	2.2	39.1	CBV-NEV	40	2.1	42.1
10	TRUVADA-KALETRA	40	2.0	37.7	EMTRIC-EFAV-TENOF	36	1.8	40.9	EMTRIC-ATAZ-RITON-TENOF	39	2.0	44.2
11	ABC-LAM-EFAV	33	1.7	39.3	EMTRIC-ATAZ-RITON-TENOF	34	1.7	42.6	KIVEXA-ATAZ-RITON	39	2.0	46.2
12	TRIZ	32	1.6	41.0	TRUVADA-RITON	29	1.4	44.0	TRUVADA-RITON	27	1.4	47.6
13	LAM-NEV-TENOF	31	1.6	42.5	CBV-EFAV	28	1.4	45.4	TRUVADA-RALT	25	1.3	48.9
14	LAM-EFAV-TENOF	28	1.4	43.9	ABC-LAM-EFAV	27	1.3	46.7	CBV-EFAV	23	1.2	50.1
15	ABC-ATAZ-RITON-TENOF	23	1.2	45.1	ABC-ATAZ-RITON-TENOF	23	1.1	47.8	KIVEXA-ATAZ	20	1.0	51.2
16	EMTRIC-EFAV-TENOF	23	1.2	46.2	EMTRIC-KALETRA-TENOF	23	1.1	48.9	TRIZ	20	1.0	52.2
17	LAM-ATAZ-RITON-TENOF	23	1.2	47.4	TRIZ	23	1.1	50.1	EMTRIC-KALETRA-TENOF	19	1.0	53.2
18	LAM-AZT-NEV	20	1.0	48.4	KIVEXA-ATAZ	22	1.1	51.2	ABC-LAM-ATAZ-RITON	18	0.9	54.2
19	TRUVADA-RITON	20	1.0	49.4	EMTRIC-NEV-TENOF	20	1.0	52.1	EMTRIC-NEV-TENOF	18	0.9	55.1
20	EMTRIC-KALETRA-TENOF	19	1.0	50.4	LAM-NEV-TENOF	20	1.0	53.1	ABC-ATAZ-RITON-TENOF	17	0.9	56.0
21	ABC-LAM-AZT	18	0.9	51.3	ABC-LAM-ATAZ-RITON	18	0.9	54.0	ABC-LAM-EFAV	16	0.8	56.8
22	LAM-D4t-NEV	17	0.9	52.1	LAM-ATAZ-RITON-TENOF	17	0.8	54.8	LAM-NEV-TENOF	16	0.8	57.7
23	LAM-KALETRA-TENOF	16	0.8	52.9	KIVEXA-KALETRA	16	0.8	55.6	TRUVADA-ATAZ	16	0.8	58.5
24	ABC-LAM-ATAZ-RITON	15	0.8	53.7	LAM-AZT-NEV	15	0.7	56.4	KIVEXA-KALETRA	15	0.8	59.3
25	ABC-LAM-RITON	15	0.8	54.4	LAM-EFAV-TENOF	15	0.7	57.1	LAM-ATAZ-RITON-TENOF	13	0.7	60.0
26	KIVEXA-KALETRA	15	0.8	55.2	LAM-D4t-NEV	14	0.7	57.8	LAM-D4t-NEV	11	0.6	60.5
27	KIVEXA-ATAZ	14	0.7	55.9	ABC-LAM-AZT	13	0.6	58.4	ABC-KALETRA-TENOF	10	0.5	61.1

28	EMTRIC-ATAZ-RITON-TENOF	13	0.7	56.5	KIVEXA-RITON	13	0.6	59.1	KIVEXA-ATAZ-RITON-TENOF	10	0.5	61.6
29	ABC-KALETRA-TENOF	12	0.6	57.1	TRUVADA-ATAZ	13	0.6	59.7	KIVEXA-RITON	10	0.5	62.1
30	EMTRIC-NEV-TENOF	11	0.6	57.7	ABC-LAM-RITON	12	0.6	60.3	LAM-EFAV-TENOF	10	0.5	62.6
31	ABC-LAM-KALETRA	10	0.5	58.2	ABC-KALETRA-TENOF	11	0.5	60.8				
32	KIVEXA-RITON	10	0.5	58.7	ABC-LAM-KALETRA	10	0.5	61.3				
33	LAM-AZT-EFAV	10	0.5	59.2								

- 
1. 491 unique ART regimens; and a total of 1,995 regimens recorded among 1,638 patients on combination ART.
  2. 492 unique ART regimens; and a total of 2,007 regimens recorded among 1,709 patients on combination ART.
  3. 473 unique ART regimens; and a total of 1,888 regimens recorded among 1,700 patients on combination ART.

NOTE: Some AHOD sites record fixed dose combination (fdc) drugs, such as Truvada, as their individual components (Emtricitabine and Tenofovir).

Table 4(a): Most frequent ARV combinations (3+ ARVs) in 2007 (A modified Table 7 from AHOD Annual report). 334 unique ART regimens; and a total of 1,995 regimens recorded among 1,638 patients on combination ART.

NOTES:

- (1) Some AHOD sites record fixed dose combination (fdc) drugs, such as Truvada, as their individual components (Emtricitabine and Tenofovir).
- (2) Some ARVs are masked with an X in order to reduce the total number of regimens and focus on the core components observed in AHOD.
- (3) Combinations with an X component are further described by whether the X's are from the NRTI class of drugs or Other (NNRTI, Fusion and Entry Inhibitors, Trial drug) or both NRTI and Other.
- (4) Combinations marked with a P indicate a Protease Inhibitor is used in the combination.
- (5) NRTI sparing is defined as a regimen without a NRTI component class drug.

Combination ARV	Count	Cumulative count (%)	Description of X		
			NRTI	Other	NRTI + Other
TRUVADA-EFAV	121	6.2			
KIVEXA-NEV	108	11.7			
TRUVADA-NEV	99	16.8			
ABC-NEV-X	87	21.2	87		
KIVEXA-EFAV	76	25.1			
TRUVADA-ATAZ-RITON	67	28.5			
CBV-NEV	64	31.8			
ATAZ-RITON-TENOF-X	56	34.7	55		1
EFAV-TENOF-X	53	37.4	53		
NEV-TENOF-X	51	40.0	51		
NEV-X	51	42.6	51		
KALETRA-TENOF-X	50	45.2	48	2	
CBV-EFAV	45	47.5			
KIVEXA-ATAZ-RITON	43	49.7			
TRUVADA-KALETRA	39	51.7			
ABC-EFAV-X	38	53.6	38		
TRIZ	32	55.2			
EFAV-X	24	56.5	24		
ABC-ATAZ-RITON-TENOF	22	57.6			
ABC-ATAZ-RITON-X	21	58.7	21		
ABC-RITON-X-P*	19	59.6	19		
ABC-X	19	60.6	19		
TRUVADA-RITON-P*	18	61.5			
ABC-KALETRA-X	17	62.4	17		
KIVEXA-KALETRA	15	63.2			

KIVEXA-ATAZ	14	63.9		
KALETRA-X	13	64.6	12	1
ABC-ATAZ-X	12	65.2	12	
TRUVADA-ATAZ-RITON-X	12	65.8	12	
ABC-KALETRA-TENOF	11	66.3	11	
RITON-DARUN-TENOF-X	10	66.9	8	2
RITON-TENOF-X-P	10	67.4	9	1
NRTI SPARING	8	0.41		N/A

\*Actual Protease Inhibitor (P) is currently unknown due to a systematic data reporting error at a select few sites. Issue is to be rectified at the source in the future.

Table 4(b): Most frequent ARV combinations (3+ ARVs) in 2008 (A modified Table 7 from AHOD Annual report). 355 unique ART regimens; and a total of 2,007 regimens recorded among 1,709 patients on combination ART.

NOTES:

- (1) Some AHOD sites record fixed dose combination (fdc) drugs, such as Truvada, as their individual components (Emtricitabine and Tenofovir).
- (2) Some ARVs are masked with an X in order to reduce the total number of regimens and focus on the core components observed in AHOD.
- (3) Combinations with an X component are further described by whether the X's are from the NRTI class of drugs or Other (NNRTI, Fusion and Entry Inhibitors, Trial Drug) or both NRTI and Other.
- (4) Combinations marked with a P indicate a Protease Inhibitor is used in the combination.
- (5) NRTI sparing is defined as a regimen without a NRTI component class drug.

Combination ARV	Count	Cumulative count (%)	Description of X		
			NRTI	Other	NRTI + Other
TRUVADA-NEV	146	7.3			
TRUVADA-EFAV	140	14.3			
KIVEXA-NEV	121	20.3			
TRUVADA-ATAZ-RITON	89	24.7			
ABC-NEV-X	88	29.1	88		
KIVEXA-EFAV	77	32.9			
ATAZ-RITON-TENOF-X	65	36.2	62	2	1
EFAV-TENOF-X	56	39.0	56		
NEV-TENOF-X	48	41.4	48		
CBV-NEV	47	43.7			
KIVEXA-ATAZ-RITON	45	45.9			
TRUVADA-KALETRA	43	48.1			
KALETRA-TENOF-X	42	50.2	39	3	
NEV-X	37	52.0	37		
ABC-EFAV-X	31	53.6	31		
CBV-EFAV	28	55.0			
TRUVADA-RITON-P*	25	56.2			
ABC-ATAZ-RITON-TENOF	23	57.3			
TRIZ	23	58.5			
ABC-ATAZ-RITON-X	22	59.6	22		
KIVEXA-ATAZ	21	60.6			
EFAV-X	20	61.6	20		
ABC-KALETRA-X	16	62.4	16		
ABC-RITON-X-P*	16	63.2	16		
KIVEXA-KALETRA	16	64.0			

RITON-DARUN-TENOF-X	14	64.7	11		3
ABC-X	13	65.4	13		
RITON-DARUN-RALT-X	13	66.0	5	5	3
TRUVADA-ATAZ	13	66.7			
ABC-ATAZ-X	11	67.2	11		
KIVEXA-RITON-P*	11	67.8			
ABC-KALETRA-TENOF	10	68.3			
TRUVADA-ATAZ-RITON-X	10	68.8	10		
<b>NRTI SPARING</b>	<b>16</b>	<b>0.80</b>			<b>N/A</b>

\*Actual Protease Inhibitor (P) is currently unknown due to a systematic data reporting error at a select few sites. Issue is to be rectified at the source in the future.



Table 4(c): Most frequent ARV combinations (3+ ARVs) in 2009 (A modified Table 7 from AHOD Annual report). 347 unique ART regimens; and a total of 1,888 regimens recorded among 1,700 patients on combination ART.

NOTES:

- (1) Some AHOD sites record fixed dose combination (fdc) drugs, such as Truvada, as their individual components (Emtricitabine and Tenofovir).
- (2) Some ARVs are masked with an X in order to reduce the total number of regimens and focus on the core components observed in AHOD.
- (3) Combinations with an X component are further described by whether the X's are from the NRTI class of drugs or Other (NNRTI, Fusion and Entry Inhibitors, Trial drug) or both NRTI and Other.
- (4) Combinations marked with a P indicate a Protease Inhibitor is used in the combination.
- (5) NRTI sparing is defined as a regimen without a NRTI component class drug.

Combination ARV	Count	Cumulative count (%)	Description of X		
			NRTI	Other	NRTI + Other
TRUVADA-EFAV	167	8.8			
TRUVADA-NEV	157	17.2			
KIVEXA-NEV	117	23.4			
TRUVADA-ATAZ-RITON	87	28.0			
KIVEXA-EFAV	70	31.7			
ATAZ-RITON-TENOF-X	65	35.1	62	2	1
ABC-NEV-X	64	38.5	64		
EFAV-TENOF-X	63	41.8	62		1
TRUVADA-KALETRA	54	44.7			
CBV-NEV	40	46.8			
NEV-TENOF-X	40	48.9	40		
KIVEXA-ATAZ-RITON	39	51.0			
KALETRA-TENOF-X	34	52.8	29	3	2
RITON-DARUN-RALT-X	25	54.1	6	12	7
TRUVADA-RALT	25	55.5			
TRUVADA-RITON-P	25	56.8			
NEV-X	24	58.1	24		
CBV-EFAV	23	59.3			
ABC-ATAZ-RITON-X	20	60.3	20		
KIVEXA-ATAZ	20	61.4			
TRIZ	20	62.4			
ABC-EFAV-X	18	63.4	18		
ABC-ATAZ-RITON-TENOF	16	64.2			
RITON-DARUN-TENOF-X	16	65.1	11	1	4
KIVEXA-KALETRA	15	65.9			

TRUVADA-ATAZ	15	66.7			
RITON-DARUN-TENOF-RALT-X	14	67.4	8	3	3
TENOF-RALT-X	12	68.1	7		5
KALETRA-X	10	68.6	10		
KIVEXA-ATAZ-RITON-TENOF	10	69.1			
NRTI SPARING	28	1.48			N/A

\* Actual Protease Inhibitor (P) is currently unknown due to a systematic data reporting error at a select few sites. Issue is to be rectified at the source in the future.